Organogenesis Holdings Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 1, 2022. This is an annual report, not a standalone fourth-quarter earnings report. Organogenesis develops, manufactures and sells regenerative medicine products for Advanced Wound Care and Surgical & Sports Medicine. It reported one operating segment and approximately 950 employees.
Financial performance and liquidity
Amounts below are in millions of dollars except per-share data and percentages.
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $468.1 | $338.3 | +38% |
| Gross profit | $353.9 | $251.0 | +41% |
| Gross margin | 75.6% | 74.2% | +1.4 percentage points |
| Operating expenses | $280.9 | $224.3 | +25% |
| Operating income | $72.9 | $26.7 | — |
| Operating margin | 15.6% | 7.9% | +7.7 percentage points |
| Net income | $94.9 | $17.2 | — |
| Diluted EPS | $0.71 | $0.15 | — |
| Adjusted EBITDA (non-GAAP) | $89.1 | $38.8 | — |
- Revenue mix: Advanced Wound Care generated $430.8 million, up 46%; Surgical & Sports Medicine generated $37.2 million, down 15%. PuraPly revenue was $198.4 million, compared with $147.3 million in 2020.
- Profit drivers and costs: Management attributed gross-profit growth to higher sales volume and a mix shift toward higher-margin products. SG&A rose 23% to $250.2 million, mainly from sales-force headcount, commissions, travel and marketing. R&D increased 53% to $30.7 million.
- Tax item: Net income included a $48.3 million income-tax benefit from releasing the valuation allowance on U.S. deferred tax assets. The reported income-tax benefit was $31.1 million after other tax items; reported earnings therefore benefited substantially from a nonrecurring valuation-allowance release.
- Cash flow and investment: Operating cash flow was $62.0 million versus $5.5 million in 2020. Investing cash outflow was $31.2 million, all reported as capital expenditures. Cash and cash equivalents were $113.9 million at year-end, versus $84.4 million; working capital was $145.0 million.
- Debt and liquidity: Year-end debt was $73.6 million, principally a $74.1 million term loan offset by $0.6 million of debt discount and issuance costs; there were no revolving borrowings. The company had $125.0 million available under its revolving facility and reported compliance with credit covenants. Management said cash, working capital, available credit and expected operating cash flows should fund operations, capital spending and debt service for at least 12 months beyond filing.
Material changes versus prior periods
- Revenue increased $129.8 million year over year, primarily from expanded sales coverage, growth with existing and new customers, adoption of placental-based products and PuraPly line extensions.
- Advanced Wound Care more than accounted for total growth; Surgical & Sports Medicine revenue declined as ReNu and NuCel distribution stopped after May 31, 2021.
- Cash from operations improved markedly, while capital expenditures rose to $31.2 million from $17.7 million. Accounts receivable increased $28.7 million during 2021, and inventory increased $9.3 million in operating cash-flow terms.
- The company refinanced and terminated its 2019 credit agreement in August 2021, recording a $1.9 million debt-extinguishment loss. Interest expense declined to $7.2 million from $11.3 million.
- Dermagraft manufacturing was suspended in Q4 2021; sales were expected to be suspended in Q2 2022 during a planned transition to Massachusetts manufacturing. Management anticipated customers would substitute Apligraf and expected no material revenue impact, but acknowledged that outcome was uncertain.
Outlook, commentary and risks
- Outlook: The filing gives no quantified FY2022 revenue, earnings or margin guidance. Management’s stated priorities include growing Advanced Wound Care, expanding Surgical & Sports Medicine, investing in clinical evidence and product development, expanding sales coverage, and consolidating manufacturing. Novachor launched in December 2021; PuraPly MZ was subject to FDA clearance, and the ReNu Phase III trial for knee osteoarthritis was underway.
- Reimbursement and regulation: Coverage varies by payer and product. Most private payers did not cover several products, including PuraPly AM, PuraPly and NuShield. Medicare reimbursement rules, bundled payments and required ASP reporting could affect pricing, utilization and revenue. The FDA could also challenge the company’s Section 361 HCT/P classification for certain placental products.
- Clinical and supply risks: ReNu’s commercial distribution was suspended in May 2021 while clinical development continued toward potential BLA approval; Phase III results and regulatory approval are uncertain. Manufacturing transitions, reliance on limited suppliers and tissue availability, and the Dermagraft interruption could disrupt sales or increase costs.
- Internal controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to an ongoing material weakness involving formal accounting procedures, review controls and segregation of duties. The auditor also reported ineffective internal control, while issuing an unqualified opinion on the financial statements. Management targeted further remediation, including an ERP implementation planned for 2022.
- Legal matter: A securities class action filed in December 2021 alleges false or misleading statements concerning billing for Affinity and PuraPly XT and alleged inducements to doctors. The company disputes the claims; damages are unquantified and the case was at an early stage.
- Other risks and unusual items: COVID-19 had not materially adversely affected FY2021 results through year-end, but future effects were uncertain. The filing also notes related-party leases, a significant stockholder group with approximately 46% beneficial ownership as of February 15, 2022, and prior-period financial statement revisions for errors the company assessed as immaterial.
Important facts for investors to verify
- How much of FY2021 net income and EPS reflects the $48.3 million deferred-tax valuation-allowance release, and what are sustainable earnings and cash-flow levels?
- Whether Advanced Wound Care growth, especially PuraPly and placental-based products, can continue amid payer coverage and Medicare reimbursement changes.
- Actual effects of the Dermagraft manufacturing and sales suspension, the Massachusetts transition, and customer substitution to Apligraf.
- ReNu Phase III progress and results, potential FDA pathway and timing, and any implications of suspending its commercial distribution.
- Progress in remediating the material weakness, including ERP deployment and evidence that controls operate effectively over time.
- Developments in the securities class action, the company’s reimbursement practices and any related regulatory or governmental inquiries.
- Debt covenant headroom, variable-rate borrowing exposure, capital-spending needs and the assumptions supporting management’s liquidity outlook.